ID   SBC-3
AC   CVCL_1678
SY   SBC3
DR   CLO; CLO_0037042
DR   EFO; EFO_0002854
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472515
DR   cancercelllines; CVCL_1678
DR   Cell_Model_Passport; SIDM00367
DR   CGH-DB; 103-1
DR   CGH-DB; 9049-4
DR   ChEMBL-Cells; CHEMBL3307308
DR   ChEMBL-Targets; CHEMBL614146
DR   Cosmic; 753610
DR   Cosmic; 889103
DR   Cosmic; 897745
DR   Cosmic; 1066171
DR   Cosmic; 1212200
DR   Cosmic; 1571746
DR   Cosmic-CLP; 753610
DR   DepMap; ACH-002197
DR   EGA; EGAS00001000978
DR   GDSC; 753610
DR   GEO; GSM17313
DR   GEO; GSM827567
DR   GEO; GSM1670405
DR   JCRB; JCRB0818
DR   LINCS_LDP; LCL-1879
DR   PharmacoDB; SBC3_1348_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1678
DR   PubChem_Cell_line; CVCL_1678
DR   Wikidata; Q54952168
RX   CelloPub=CLPUB00132;
RX   DOI=10.4044/joma1947.104.9-10_905;
RX   PubMed=2540905;
RX   PubMed=3012965;
RX   PubMed=3032107;
RX   PubMed=8286010;
RX   PubMed=9227790;
RX   PubMed=9290701;
RX   PubMed=9413215;
RX   PubMed=9615743;
RX   PubMed=9914787;
RX   PubMed=10358721;
RX   PubMed=10628341;
RX   PubMed=12107105;
RX   PubMed=15016488;
RX   PubMed=15185009;
RX   PubMed=20215515;
RX   PubMed=22399608;
RX   PubMed=23066953;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=3012965); 21.6 hours (PubMed=8286010; PubMed=9615743; PubMed=10628341); 14 hours (PubMed=9914787); ~30 hours (Note=Lots 012699 and 07262007), ~21 hours (Note=Lot 09082011) (JCRB=JCRB0818).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.39%; East Asian, North=77.93%; East Asian, South=21.68%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D5S818: 12,13
ST   D7S820: 12,13
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   CelloPub=CLPUB00132;
RA   Kishimoto N., Ohnoshi T., Hiraki S., Miyake K., Ozawa S., Tamura T.,
RA   Numata K., Kawahara N., Tamura R., Miyamoto H., Nishii K., Kimura I.;
RT   "Establishment and characterization of five cell lines from human
RT   small cell carcinoma of the lung.";
RL   Nihon Haigan Gakkai 24:644-644(1984).
//
RX   DOI=10.4044/joma1947.104.9-10_905;
RA   Kishimoto N.;
RT   "Studies on cell biology and chemotherapy of lung cancer using tissue
RT   culture techniques. Part 2. Biological characteristics of five newly
RT   established small cell lung cancer cell lines.";
RL   Okayama Igakkai Zasshi 104:905-913(1992).
//
RX   PubMed=2540905;
RA   Takahashi T., Obata Y., Sekido Y., Hida T., Ueda R., Watanabe H.,
RA   Ariyoshi Y., Sugiura T., Takahashi T.;
RT   "Expression and amplification of myc gene family in small cell lung
RT   cancer and its relation to biological characteristics.";
RL   Cancer Res. 49:2683-2688(1989).
//
RX   PubMed=3012965; DOI=10.18926/AMO/31923;
RA   Miyamoto H.;
RT   "Establishment and characterization of an adriamycin-resistant subline
RT   of human small cell lung cancer cells.";
RL   Acta Med. Okayama 40:65-73(1986).
//
RX   PubMed=3032107;
RA   Kimura I., Ohnoshi T., Hiraki S., Miyamoto H.;
RT   "Establishment of adriamycin-resistant human small-cell lung cancer
RT   cells in culture: analysis of the mechanism of resistance and
RT   cross-resistance.";
RL   Gan To Kagaku Ryoho 14:830-836(1987).
//
RX   PubMed=8286010;
RA   Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.;
RT   "Inhibitory effects of cholera toxin on in vitro growth of human lung
RT   cancer cell lines.";
RL   Anticancer Drug Des. 8:417-428(1993).
//
RX   PubMed=9227790; DOI=10.18926/AMO/30795;
RA   Matsuo K., Kiura K., Ueoka H., Tabata M., Shibayama T., Matsumura T.,
RA   Takigawa N., Hiraki S., Harada M.;
RT   "Growth inhibitory effects of antifolates against an
RT   adriamycin-resistant human small cell lung cancer cell line.";
RL   Acta Med. Okayama 51:121-127(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9413215;
RA   Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K.,
RA   Hiraki A., Ueoka H., Harada M.;
RT   "Small cell lung cancer can express CD34 antigen.";
RL   Anticancer Res. 17:3627-3632(1997).
//
RX   PubMed=9615743;
RA   Moritaka T., Kiura K., Ueoka H., Tabata M., Segawa Y., Shibayama T.,
RA   Takigawa N., Ohnoshi T., Harada M.;
RT   "Cisplatin-resistant human small cell lung cancer cell line shows
RT   collateral sensitivity to vinca alkaloids.";
RL   Anticancer Res. 18:927-933(1998).
//
RX   PubMed=9914787; DOI=10.1111/j.1349-7006.1998.tb00513.x;
RA   Nomoto T., Nishio K., Ishida T., Mori M., Saijo N.;
RT   "Characterization of a human small-cell lung cancer cell line
RT   resistant to a new water-soluble camptothecin derivative, DX-8951f.";
RL   Jpn. J. Cancer Res. 89:1179-1186(1998).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=10628341;
RA   Ikubo S., Takigawa N., Ueoka H., Kiura K., Tabata M., Shibayama T.,
RA   Chikamori M., Aoe K., Matsushita A., Harada M.;
RT   "In vitro evaluation of antimicrotubule agents in human small-cell
RT   lung cancer cell lines.";
RL   Anticancer Res. 19:3985-3988(1999).
//
RX   PubMed=12107105; DOI=10.1016/S0002-9440(10)64172-7;
RA   Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T.,
RA   Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S.,
RA   Inazawa J.;
RT   "A novel target gene, SKP2, within the 5p13 amplicon that is
RT   frequently detected in small cell lung cancers.";
RL   Am. J. Pathol. 161:207-216(2002).
//
RX   PubMed=15016488; DOI=10.1016/S0140-6736(04)15693-6;
RA   Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S.,
RA   Nakagawa K., Nomura H., Ishikawa Y.;
RT   "Two prognostically significant subtypes of high-grade lung
RT   neuroendocrine tumours independent of small-cell and large-cell
RT   neuroendocrine carcinomas identified by gene expression profiles.";
RL   Lancet 363:775-781(2004).
//
RX   PubMed=15185009; DOI=10.1007/s00262-004-0533-9;
RA   Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H.,
RA   Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T.,
RA   Fujisawa T.;
RT   "Correlation between interleukin 6 production and tumor proliferation
RT   in non-small cell lung cancer.";
RL   Cancer Immunol. Immunother. 53:786-792(2004).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22399608;
RA   Tsuchida T., Yamane H., Ochi N., Tabayashi T., Hiraki A., Nogami N.,
RA   Takigawa N., Kiura K., Tanimoto M.;
RT   "Cytotoxicity of activated natural killer cells and expression of
RT   adhesion molecules in small-cell lung cancer.";
RL   Anticancer Res. 32:887-892(2012).
//
RX   PubMed=23066953; DOI=10.1111/cas.12045;
RA   Kubo T., Takigawa N., Osawa M., Harada D., Ninomiya T., Ochi N.,
RA   Ichihara E., Yamane H., Tanimoto M., Kiura K.;
RT   "Subpopulation of small-cell lung cancer cells expressing CD133 and
RT   CD87 show resistance to chemotherapy.";
RL   Cancer Sci. 104:78-84(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//